I-PBAC iyindikimba yochwepheshe ezimele eqokwe uHulumeni wase-Australia. Amalungu ahlanganisa odokotela, ochwepheshe bezempilo, osomnotho bezempilo nabamele abathengi.
Indima yabo ukuncoma imithi emisha ezofakwa ohlwini lwezinhlelo zezinzuzo zemithi (PBS). Awukho umuthi omusha ongafakwa ohlwini ngaphandle uma ikomidi lenza isincomo esihle. I-PBAC ihlangana kathathu ngonyaka, ngokuvamile ngoMashi, Julayi noNovemba.
Kuleli khasi:
I-ajenda yomhlangano ye-PBAC ezayo:
November 2020
Ukuhanjiswa kwe-Lymphoma ne-CLL ku-ajenda ezayo
Novemba 2020 ukuhanjiswa kwe-lymphoma/CLL ku-ajenda
| Uhlobo lokuthumela | Igama lesidakamizwa nomxhasi | Uhlobo lwezidakamizwa nokusetshenziswa | Ukufakwa kuhlu kucelwe umxhasi nenjongo |
| Ukufakwa kuhlu okusha (ukuhanjiswa okuncane) | Ibrutinib | I-Lymphocytic leukemia engapheli (CLL); I-lymphocytic lymphoma encane (SLL); I-Mantle cell lymphoma | Ukucela isiphathimandla Ukufakwa kuhlu okudingekayo kwethebhulethi ye-ibrutinib ngaphansi kwezimo ezifanayo nekhepsuli esivele esohlwini. |
| Ukufakwa kuhlu okusha (ukuhanjiswa okuncane) | Mogamulizumab (Kyowa Kirin) | I-Cutaneous T-cell lymphoma (CTCL) | Ukuhambisa kabusha ukucela iSigaba 100 (uxhaso olusebenzayo lwe-chemotherapy) Igunya Ukufakwa ohlwini okudingekile kweziguli ezine-CTCL ebuyele emuva noma engasebenzi kahle ezike zelashwa ngaphambilini okungenani ngokwelashwa okuhleliwe okukodwa. |
Imiphumela yomhlangano we-PBAC
July 2020
Ukuhanjiswa kwe-Lymphoma ne-CLL kanye nemiphumela
Julayi 2020 Imiphumela yomhlangano we-PBAC yokuthunyelwa kwe-lymphoma ne-CLL
| Isidakamizwa, umxhasi, uhlobo lokuhambisa | Uhlobo lwezidakamizwa noma ukusetshenziswa | Ukufakwa ohlwini kucelwe umxhasi/inhloso yokuhambisa | Umphumela we-PMAC |
IVenetoclax (AbbVie) Shintshela ohlwini (okuthunyelwe okuncane) | I-lymphocytic leukemia engapheli (CLL) | Ukuhambisa kabusha ukucela Ukufakwa ohlwini Okudingekayo, ngokuhambisana ne-Obinutuzumab, ukuze kulashwe iziguli ezine-CLL ezinezimo ezihlala zikhona ze-fludarabine based chemotherapy. | I-PBAC yancoma ukufakwa kuhlu kwe-venetoclax kuhlanganiswe ne-obinutuzumab yokwelashwa komugqa wokuqala kweziguli ezine-CLL ezinezimo ezihlala isikhathi eside futhi ezingafanelekile ku-fludarabine based chemo- immunotherapy. |
| I-Acalabrutinib (AstraZeneca) | I-Chronic lymphocytic leukemia (CLL) noma i-lymphocytic lymphoma encane (SLL) | Ukucela Isiphathimandla Esidingekayo sokufakwa kuhlu kokwelashwa kweziguli (mhlawumbe njenge-monotherapy noma kuhlanganiswe ne-obinutuzumab) ezine-CLL ezazingazange zilashwe ngaphambilini noma i-SLL ezazibhekwa njengezingafaneleki ukwelashwa nge-analogue ye-purine. Isicelo sesibili kwakungesokusetshenziswa kuphela eqenjini elincane leziguli ezinokususwa kwe-17p. | I-PBAC ayizange batusa ukufakwa kuhlu kwe-acalabrutinib, ukuze isetshenziswe njenge-monotherapy noma ihlanganiswe ne-obinutuzumab, ukuze kulashwe umugqa wokuqala weziguli ezine-CLL noma i-SLL ezibhekwa njengezingafaneleki ukwelashwa nge-purine analogue. I-PBAC icabange ukuthi isilinganiso esikhuphukayo sokuphumelela kwezindleko sasiphezulu ngendlela engamukeleki futhi asiqinisekile ngentengo ehlongozwayo. |
Mogamulizumab (Kyowa Kirin) | I-Cutaneous T-cell lymphoma (CTCL) | Ukucela Ukufakwa Kuhlu KweSigaba 100 (Uxhaso Oluphumelelayo Lwekhemotherapy) Igunya Elidingekayo (Lolubhaliwe) lweziguli ezine-CTCL ebuye yabuyela emuva noma engasebenzi kahle ezike zelashwa ngaphambilini okungenani ngokwelashwa okuhleliwe okukodwa kwangaphambili. | I-PBAC ayizange iphakamise ukufakwa kuhlu kwe-mogamulizumab ukuze zelashwe iziguli ezine-CTCL ebuyele emuva noma engasebenzi kulandela okungenani ukwelashwa okuhleliwe okukodwa kwangaphambili kwalesi simo. I-PBAC icabange ukuthi izinga lenzuzo ye-mogamulizumab mayelana nokuphila kwamahhala kokuqhubekela phambili kanye nokusinda kukonke kwakungaqinisekiswa. Ukwengeza, i-PBAC ibheke ukuthi isilinganiso sokunyuka kokuphumelela kwezindleko sasiphezulu ngendlela engamukeleki futhi singaqinisekile ngenani elihlongozwayo, futhi umthelela wezezimali olinganiselwe wawungaqinisekile. |
I-ajenda yomhlangano kaMashi 2020 ye-PBAC ye-lymphoma/CLL kanye nokulinda okuvelele kokuthatha isinyathelo kusukela ngoNovemba 2019
| Igama lesidakamizwa nomxhasi | Uhlobo oluncane | Ukufakwa kuhlu kuceliwe kanye nenjongo | Umphumela we-PBAC |
| I-Ibrutinib (Janssen) | I-Chronic lymphocytic leukemia (CLL) noma i-lymphocytic lymphoma encane (SLL) | Ukuhambisa kabusha ukucela imbuyiselo ye-PBS yokwelashwa kwe-CLL noma i-SLL enobufakazi bokususwa kwe-chromosome ye-17p eyodwa noma ngaphezulu | I-PBAC income ukufakwa kuhlu kwe-PBS kwe-ibrutinib yokwelashwa komugqa wokuqala nge-CLL/SLL ngokususwa okungu-17p -zisalinde ukufakwa ohlwini, kusukela ngoNovemba 2019 |
| I-Acalabrutinib (AstraZeneca) | I-Chronic lymphocytic leukemia (CLL) noma i-lymphocytic lymphoma encane (SLL) | Ukucela uhlu lwe-PBS lokwelashwa kweziguli ezine-CLL ebuyele emuva noma ephikisayo noma i-SLL engafanele ukwelashwa nge-analogue ye-purine | I-PBAC income ukufakwa kuhlu kwe-acalabrutinib yokwelashwa kweziguli ezine-R/R CLL/SLL ekwelashweni komugqa wesibili - ilinde ukufakwa kuhlu lwe-PBS kusukela ngoMashi 2020 |
| I-Pembrolizumab (MSD) | I-Primary mediastinal B-cell lymphoma (PMBCL) | Ukuhambisa kabusha ukucela ukufakwa kuhlu kwe-PBS ukuze kuphathwe i-PMBCL ebuyele emuva noma ephikisayo | I-PBAC income ukufakwa kuhlu kwe-PBS kwe-pembrolizumab ye-R/R PMBCL - wilindele ukufakwa ohlwini lwe-PBS kusukela ngoMashi 2020 |
